Zoetis Inc. (ZTS)
NYSE: ZTS · Real-Time Price · USD
176.96
+0.25 (0.14%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.

The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.

In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.

It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.

Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Inc.
Zoetis logo
Country United States
Founded 1952
IPO Date Feb 1, 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 14,100
CEO Kristin Peck

Contact Details

Address:
10 Sylvan Way
Parsippany, New Jersey 07054
United States
Phone 973 822 7000
Website zoetis.com

Stock Details

Ticker Symbol ZTS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001555280
CUSIP Number 98978V103
ISIN Number US98978V1035
Employer ID 46-0696167
SIC Code 2834

Key Executives

Name Position
Kristin C. Peck Chief Executive Officer and Director
Dr. Robert J. Polzer Ph.D. Executive Vice President and President of Research and Development

Latest SEC Filings

Date Type Title
Nov 12, 2024 8-K Current Report
Nov 4, 2024 10-Q Quarterly Report
Nov 4, 2024 8-K Current Report
Oct 10, 2024 8-K Current Report
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Aug 1, 2024 8-K Current Report
Jun 26, 2024 11-K Annual report of employee stock purchase, savings and similar plans
May 30, 2024 SD Form - SD
May 24, 2024 8-K Current Report